Strides Pharma Q1 FY27 Results

Strides Pharma Science Ltd announced its Q1 FY27 financial results, reporting a 13% year-on-year consolidated revenue growth to ₹1,215.5 crore. The company's operational Profit After Tax (PAT) rose by 8% to ₹123.1 crore, while reported PAT stood at ₹165.5 crore, boosted by a one-time gain from the divestment of the Pivot Path business.

Reader Takeaway: Core profit growth steady, but monitor US FDA status and freight costs.

What just happened

Strides Pharma reported a consolidated revenue of ₹1,215.5 crore for Q1 FY27, a 13% increase compared to the same period last year. The company achieved an EBITDA of ₹229.8 crore, with an EBITDA margin of 18.2%. Operational PAT grew 8% year-on-year to ₹123.1 crore. Reported PAT was ₹165.5 crore, which includes a net gain of ₹53.4 crore from the divestment of the Pivot Path business.

Why this matters

The results indicate steady operational performance despite external challenges. The revenue growth, particularly from Ex-US markets, highlights diversification efforts. The increase in operational PAT shows the core business's resilience. Investors will be looking at the company's strategy to drive its US business in the second half of the fiscal year.

The backstory

Strides Pharma has been focusing on strengthening its operational performance and diversifying its revenue streams. In recent periods, the company has been managing supply chain disruptions and regulatory scrutiny, particularly from the USFDA. The divestment of non-core assets like Pivot Path aims to streamline operations and focus on key growth areas.

What changes now

With a 13% revenue growth and an improved debt-to-EBITDA ratio of 1.52x, the company is positioning itself for future growth. Management's confidence in a stronger second half for the US business, driven by new product launches and approvals, suggests a potential upturn. The company is working towards its target of a $375 million North America business by FY28.

Risks to watch

Key risks include the outcome of the USFDA's review of the Bangalore plant, potential further impacts of geopolitical disruptions on freight costs and supply chains, and the execution of new product launches in the competitive US market. The 'soft' US market in the first half of the year needs to translate into the expected H2 recovery.

Peer comparison

Strides Pharma's revenue growth of 13% in the pharmaceutical sector is a positive sign. However, profitability metrics should be compared against peers after normalizing for one-time gains. Companies facing similar supply chain challenges and USFDA scrutiny will present a more direct comparison.

Context metrics (time-bound)

• Revenue Growth: 13% YoY Consolidated
• Operational PAT: ₹123.1 crore (8% YoY increase)
• Net Debt-to-EBITDA: 1.52x (improved from 1.55x)
• US Revenue: ₹628.2 crore ($68 million)
• Ex-US Revenue: ₹587.5 crore (17% YoY growth)

What to track next

Investors should monitor the USFDA's feedback on the Bangalore plant and track the progress of new product launches. The performance of the US business in H2 FY27 and the company's ability to manage freight costs will be crucial indicators.